Plain-English translation of NCT06986486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new treatment approach for a rare type of bile duct cancer called perihilar cholangiocarcinoma. The study combines chemotherapy (using gemcitabine and cisplatin), an immunotherapy medication called durvalumab, focused radiation therapy, and ultimately a liver transplant. The goal is to shrink the tumor first so that patients can then receive a new liver to replace the one affected by cancer.
Perihilar cholangiocarcinoma is an aggressive cancer that often cannot be surgically removed. This trial exists because standard treatments have not worked well for patients with this cancer, and researchers believe that combining multiple treatments before transplant might help more patients survive longer and have better outcomes.
You likely qualify if…
You likely don't qualify if…
You would first have a minimally invasive surgical procedure to check that your cancer has not spread. If you qualify, you'll receive chemotherapy with the immunotherapy medication over several months, followed by focused radiation therapy to the tumor. During this time, you'll have regular scans and blood tests every two months to monitor how the cancer is responding. Once the tumor has shrunk or stopped growing, you'll be evaluated and listed for a liver transplant, with the goal of receiving a new liver within 90 days of being listed.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Italy
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Enrollment target
~8 participants
Started
June 2025
Primary completion
January 2030
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vincenzo Mazzaferro, MD, PhD
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.